GeoVax 2022 net loss $14.0M, cash $27.6M; clinical trials expand

GeoVax Labs, Inc.

Net loss for 2022 was $14.0M, versus $18.6M in 2021; R&D expenses fell to $9.1M from $15.6M.
Cash balance at Dec 31, 2022: $27.6M, up from $11.4M in 2021; raised $35.4M from equity and warrant exercises.
Phase 1/2 trial of Gedeptin® for advanced head & neck cancer expanded to three NCI Cancer Centers.
GEO-CM04S1 COVID-19 vaccine advancing in two Phase 2 trials; data show robust T cell and antibody responses.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GeoVax Labs, Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 23, 2023, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the year ended December 31, 2022.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

GeoVax Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-007711

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.